Abbott Laboratories Earnings Recaps
Q2 2026
Jul 18, 2026
Abbott delivered better-than-expected sales growth and raised its EPS guidance, driving a strong 12.8% stock gain as durable demand across key segments and pipeline progress reassured investors.
Key takeaways
- Reported 4.8% comparable sales growth in Q2, accelerating from the prior two quarters.
- Adjusted EPS of $1.31 came above the midpoint of guidance, prompting an EPS outlook raise to $5.45–$5.60 for 2026.
- Diagnostics showed mixed results: core laboratory US business grew 7.5%, cancer diagnostics climbed 13%, but rapid and molecular diagnostics declined 8% due to a weak respiratory testing season.
- Nutrition sales improved sequentially by $125 million, with international pediatric nutrition growing 6.5% and U.S. adult nutrition volumes increasing double digits post-price adjustments.
- Pipeline progress remains strong, with multiple product launches and clinical trial enrollments planned in the next 12 months, supporting future growth potential.
Q1 2026
Apr 16, 2026
Abbott delivered aligned first-quarter results with steady earnings and achieved a key strategic milestone with the acquisition of Exact Sciences, enhancing its diagnostics leadership and growth prospects.
Key takeaways
- Adjusted EPS of $1.15 met guidance despite headwinds from early financing costs and a weaker respiratory season.
- Completed the Exact Sciences acquisition, adding ~$3 billion in expected 2026 sales and accelerating long-term growth trajectory.
- Diagnostics sales grew 2%, with Core Lab up 3%, while Molecular Diagnostics declined 10% due to weaker respiratory testing demand.
- Cancer Diagnostics posted 13% growth driven by strong international performance and Cologuard.
- Medical Devices revenue increased 8.5%, led by robust cardiovascular product sales, supported by pipeline advancements and clinical trial initiatives.
Q3 2025
Oct 16, 2025
Abbott Laboratories reported a robust 7.5% organic sales growth in Q3 2025, primarily driven by a strong performance in medical devices and established pharmaceuticals, despite a decline in COVID test sales.
Key takeaways
- Earnings per share rose to $1.30, reflecting high single-digit growth year-over-year, excluding COVID test impacts.
- New product launches contributed nearly $5 billion in sales this quarter, adding over 100 basis points to organic sales growth.
- Medical Devices segment grew by 12.5%, led by solid performances in diabetes care and electrophysiology.
- Established Pharmaceuticals experienced high single-digit growth, driven by strong contributions from core markets and therapeutic areas.
- Strategic investments in nutrition products are set to leverage favorable consumer trends, evidenced by new launches in the adult nutrition segment.